#eularcongress

Introduction to Rheumatic and Musculoskeletal Diseases (RMDs) Chronic Musculoskeletal Pain Connective tissue diseaseJuvenile Idiopathic ArthritisOsteoarthritis Soft Tissue Rheumatism (STR)

Rheumatic diseases, often known as musculoskeletal disorders, are characterized by pain and a consequent loss in the range of motion and function in various regions of the musculoskeletal system; in some diseases, inflammation manifests itself as swelling, redness, and warmth in the affected areas. In rheumatic disorders, which are autoimmune and inflammatory diseases, the immune system targets the joints, muscles, bones, and organs. Rheumatic disorders are sometimes included under the umbrella term "arthritis," which covers more than 100 diseases and symptoms. In some situations, the disorders impact the joints, tendons, ligaments, bones, muscles, and related organs.

Rheumatic and musculoskeletal illnesses (RMDs) afflict both children and adults, and there are over 200 different forms of RMDs. A weakened immune system or inflammation, infections, and slow deterioration of the joints, muscles, and bones are the most common causes of this category of disorders. Many rheumatic and musculoskeletal disorders are chronic, deteriorate with time, are painful, and impede one's ability to function. These illnesses can cause major disability in severe cases, lowering the quality of life and shortening life expectancy.

The Most Common Musculoskeletal Disorders: 

Chronic musculoskeletal pain (CMP) is defined as musculoskeletal pain that persists for more than 3–6 months and has no recognized underlying, significant, or specific pathology.

Connective tissue disorders are a group of illnesses marked by multi-organ inflammation and autoimmune responses. Although the condition is rather uncommon, when it manifests itself acutely, it can be life-threatening and necessitates rapid medical attention to avoid multi-system damage.

For at least 6 weeks, the illness causes inflammation, discomfort, and swelling in one or more joints. Juvenile arthritis is a common name for it. According to Versus Arthritis (2018), almost 12,000 children under the age of 16 in the United Kingdom were diagnosed with the disease in 2018.

It is the most frequent type of arthritis, and it refers to a clinical syndrome characterized by joint pain, functional limitations, and a poor quality of life. Frequently, the knee, hip, and joint regions are impacted.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a debilitating, chronic illness in which the immune system affects the synovial lining of joints and other organs. If the joint is not treated, it can lose its shape and alignment, causing bone erosion and eventually leading to joint destruction and irreversible impairment. It mainly affects the tiny joints of the hands and feet, with a symmetrical distribution on both sides, though any synovial joint can be affected.

Tendonitis, fasciitis, fibromyalgia, and bursitis are all examples of soft-tissue rheumatism, which affects the tissue around a joint, such as ligaments and tendons. STR encompasses a wide range of health issues, the majority of which are inadequately defined by diagnostic criteria and case definitions.

Different Types of Musculoskeletal Imaging Tools and Techniques

X-Ray

Ultrasound

Computed tomography (CT)

Magnetic resonance imaging (MRI)

PET-CT and PET-MRI

Conclusion 

Previously, musculoskeletal imaging techniques were primarily in the form of plain X-rays. However, it has numerous drawbacks in terms of seeing several soft-tissue disorders. Following that, the emergence of ultrasound as a diagnostic tool signaled the beginning of the non-radiation era. As a result, novel diagnostic imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) were developed, allowing for the delineation of multidirectional and high-resolution information about a variety of other clinical disorders.

The ability to recognize the small changes in imaging findings between pathologic situations willaid in the diagnosis and treatment of MSK diseases.

For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022

Some of the Latest Abstracts launched in EULAR 2022:

Rheumatic and Musculoskeletal Diseases Highlights

Deucravacitinib: A Ray of Hope after a decade of wait! BMS plans to progress its potential game-changer oral TYK2 inhibitor into late-stage clinical development

Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs

Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial 

Diagnostic Imaging Equipment Market

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

Invasive Candidiasis Market

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW.

Sialidosis Market 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.  

Pain Management Devices Market

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Also, take a glance at the Blogs by DelveInsight:

How Metaverse is Set to Transform the Healthcare Dynamics?

Role of Mobile Technology in Hemophilia Management

How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry?

Upadacitinib Highlights: EULAR 2022Efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis: a double-blind, randomized, placebo-controlled Phase III trial (Abstract # OP0016)

Abbvie's upadacitinib beat placebo in terms of signs and symptoms, pain, function, disease activity, and MRI-detected spine inflammation at Week 14 of the Phase III SELECT-AXIS 2 clinical trial.

According to the data, upadacitinib significantly enhanced the number of nr-axSpA patients who met the primary endpoint (45 percent) of ASAS40 at Week 14 as compared to placebo (23 percent ). Secondary endpoints included the Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Functional Index (BASFI), and MRI Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac joints, and Ankylosing Spondylitis Quality of Life (ASQoL), as well as low disease activity. During 14 weeks of JAK inhibitor treatment, 48 percent and 46% of patients in the upadacitinib and placebo groups, respectively, had adverse events, with no fatalities or significant adverse cardiovascular events.

KOL Insights

This is the first study to show that the JAK inhibitor upadacitinib could be a therapeutic option in patients with active non-radiographic spondyloarthritis. The findings suggest that upadacitinib, an oral therapy, has the potential to help patients with nr-axSpA take control of their disease by reducing inflammation, relieving pain, and improving function.

Conclusion 

The disease activity of 30% of people with SpA cannot be controlled with currently approved drugs, according to the current spondyloarthritis treatment regimen.

JAK inhibitors are the most recent class of synthetic (nonbiologic) disease-modifying antirheumatic medicines (DMARDs) that have been shown to be effective in clinical trials for the treatment of axSpA, and their oral route of administration makes them a more convenient treatment option than other therapies, potentially leading to higher compliance. Rheumatoid arthritis and psoriatic arthritis are two conditions for which the medication is already licensed.

Furthermore, Abbvie has previously demonstrated its leadership in the axSpA market with the approval of its lead candidate Rinvoq (upadacitinib) for the treatment of active ankylosing spondylitis. After 14 weeks of treatment, upadacitinib 15 mg once daily showed significant improvements in the signs and symptoms of nr-axSpA compared to placebo, indicating for the first time the possible use of upadacitinib as a treatment option in patients with nr-axSpA.

For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022

Some of the Latest Abstracts launched in EULAR 2022:

Rheumatic and Musculoskeletal Diseases Highlights

Deucravacitinib: A Ray of Hope after a decade of wait! BMS plans to progress its potential game-changer oral TYK2 inhibitor into late-stage clinical development

Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs

Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial

Diagnostic Imaging Equipment Market

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

Invasive Candidiasis Market

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW.

Sialidosis Market 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Pain Management Devices Market

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Also, take a glance at the Blogs by DelveInsight:

How Metaverse is Set to Transform the Healthcare Dynamics?

Role of Mobile Technology in Hemophilia Management

How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry?

EULAR 2022: IL-17A & IL-17F with bimekizumab

Bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy and safety from BE MOBILE 2, a Phase III, multicenter, randomized, placebo-controlled study (Abstract # OP0019)

Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The BE MOBILE 2 trial, displayed a positive safety and efficacy results in patients who were affected by ankylosing spondylitis and poor response or intolerance to two nonsteroidal anti-inflammatory drugs and prior exposure to no more than one TNF inhibitor.

In Week-16, the bimekizumab group showed 44.8% ASAS40 response rates, in contrast to 22.5% response rates in the placebo group. In Week-24, the follow-up for ASAS40 response rates were 53.8% for patients who received bimekizumab throughout the study and 56.8% response rates for those who switched to placebo at Week-16. 54.3% of the patients experienced treatment-emergent adverse events (TEAEs), who were treated with bimekizumab at weeks 0-16. Patients with active As who were treated with bimekizumab showed rapid and clinically positive reductions in key signs and symptoms of the disease, with ASDAS <2.1 by week 24. In terms of secondary endpoints, objective signs of inflammation, as described by CRP levels and MRI inflammation of the sacroiliac joints and spine, were notably reduced in bimekiumab-treated patients. Commonly, around 7.7% of the individuals treated with bimekizumab were affected by Nasopharyngitis.

Conclusion

The BE MOBILE 2 Phase III study met all its primary and secondary endpoints. Between the TNFi-navie and TNFi-experienced patients, consistent ASA40 response rates were observed.

In patients with active AS, dual inhibition of IL-17A and IL-17F with bimekizumab resulted in rapid, clinically relevant improvements in efficacy outcomes versus placebo. These results will open up the scope for further exploration of humanized monoclonal IgG1 for AS.

For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022

Some of the Latest Abstracts launched in EULAR 2022:

Deucravacitinib: A Ray of Hope after a decade of wait! BMS plans to progress its potential game-changer oral TYK2 inhibitor into late-stage clinical development

Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs

Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial

Rheumatic and Musculoskeletal Diseases Highlights

Diagnostic Imaging Equipment Market

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

Invasive Candidiasis Market

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW. 

Sialidosis Market 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Pain Management Devices Market

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Also, take a glance at the Blogs by DelveInsight:

How Metaverse is Set to Transform the Healthcare Dynamics?

Role of Mobile Technology in Hemophilia Management

How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry?

Upadacitinib for treatment of Nonradiographic Axial Spondyloarthritis

Janus Kinase (JAK) inhibitors have been recognized as a probable treatment option for  Ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). Upadacitinib, an inhibitor by JAK, has shown efficacy and safety in treating  Ankylosing spondylitis (AS), and so far no JAK inhibitor studies in non-radiographic axSpA (nr-SpA) have done such.

The efficacy and safety findings of upadacitinib (RINVOQ) in patients with nr-axSpA and patients with AS who have not responded to biologic disease-modifying antirheumatic drugs (bDMARDs) are highlighted in the SELECT-AXIS 2 trial.

SELECT-AXIS 2 (Study 2) is a Phase III trial evaluating upadacitinib's effectiveness and safety in patients with active nr-axSpA.

At Week 14, upadacitinib met the primary endpoint of the Assessment in SpondyloArthritis International Society (ASAS) 40 response and the majority of the secondary endpoints, according to the interim results. At Week 14, upadacitinib-treated patients had a significantly higher rate of ASAS40 response (45%) than placebo-treated patients (23 percent ).

In January of this year, the company submitted applications to the US FDA and the European Medicines Agency (EMA) for approval of upadacitinib (RINVOQ, 15 mg once daily) for the treatment of adults with active nr-axSpA and objective signs of inflammation who have failed to respond to nonsteroidal anti-inflammatory drugs (NSAIDs).

Conclusion

The disease activity of 30% of individuals with SpA cannot be controlled with currently approved medicines, according to the current spondyloarthritis therapy regimen.

JAK inhibitors are a new family of nonbiologic (synthetic) disease-modifying antirheumatic drugs (DMARDs) that have shown to be successful in clinical trials for the treatment of psoriatic arthritis and ankylosing spondylitis. Furthermore, because it is administered orally, it is a more convenient treatment option than other medications, which may lead to higher compliance.

For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022

Some of the Latest Abstracts launched in EULAR 2022:

Novel biomarkers in Rheumatic and Musculoskeletal Diseases

Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs

Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial

Rheumatic and Musculoskeletal Diseases Highlights 

Diagnostic Imaging Equipment Market

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

Invasive Candidiasis Market

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW. 

Sialidosis Market 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Filgrastim Biosimilar Insight

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Pain Management Devices Market

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Also, take a glance at the Blogs by DelveInsight:

How Metaverse is Set to Transform the Healthcare Dynamics?

Role of Mobile Technology in Hemophilia Management

How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry?